AMORPHICAL
Nira R. currently serves as the Chief Marketing Officer at AMORPHICAL since December 2022 and has previously held the position of Israel Marketing Director at Taro Pharmaceuticals from October 2014 to November 2022. Prior experience includes serving as Sales and Marketing Director at Dexcel Pharma from July 2000 to April 2014. Nira R. earned a professional certificate in Management from Bar-Ilan University between May 2006 and July 2007 and holds a degree in Marketing and Commercial from the Israeli Marketing Association, along with earlier studies at Tel Aviv University from 1991 to 1994.
This person is not in any teams
This person is not in any offices
AMORPHICAL
Pioneer Israeli Biotechnology Company Established in 2004 developing novel solutions for number of major diseases. Amorphical has successfully developed a unique and stable form of Amorphous Calcium Carbonate (ACC), in nano-particle form (20-80 nm) employing proprietary process based on biomimicry-searching methods utilized by certain mammals. The unique features of ACC have demonstrated novel modes of actions that enable disease treatment in a number of conditions, as well as performance improvement of cells and organs. ACC has a much higher solubility than crystalline calcium carbonate (CCC) at mildly acidic conditions and neutral pH (100 times higher), compared to all similar calcium products in the market including Pfizer’s and GNC’s. ACC consists of nanometric primary particles in the range of 20 to 80 nanometers that are slightly agglomerated. ACC has a remarkable higher (double) calcium absorption, compared to other calcium supplement substances. ACC has remarkable higher calcium bioavailability and higher bioactivity, which is attributed to ACC’s capability to deliver the carbonate domains as a solid nanometric buffer.